TGFBR2 and breast carcinoma: In addition, USP8 inhibition triggers MHC‐I expression and innate immune response through activating the NF‐κB signaling.[50] In breast cancer, USP8 directly deubiquitinates and stabilizes the type II TGF‐β receptor TβRII.